Form 4 Filing for Camp4 Therapeutics Corp

Daniel Tardiff, Chief Scientific Officer of Camp4 Therapeutics Corp, was granted 145,500 stock options on December 11, 2025. These options, with an exercise price of $6.01, allow for the purchase of common stock. The options have an exercise date that is subject to footnote F1, indicating a vesting schedule that begins on December 1, 2025. The vesting occurs one-third on the first anniversary of the vesting start date, with the remainder vesting in equal monthly installments over the subsequent 24 months, contingent upon continued service. The options expire on December 10, 2035. Following this transaction, Mr. Tardiff directly owns 145,500 shares underlying these options. The filing is a Form 4, indicating a change in beneficial ownership.